Revolution Medicines jumps after pancreatic cancer drug extends survival

Revolution Medicines

13/04/2026 14:44

Updates

** Shares of biotech firm Revolution Medicines RVMD.O jump 35% to $133

** Company says its experimental pill daraxonrasib in a late-stage study met main goals of improving how long patients with pancreatic cancer lived overall and how long the disease stayed under control

** Patients on the drug showed median overall survival of 13.2 months vs 6.7 months on chemotherapy in the trial, which enrolled participants whose cancer worsened after prior treatment

** Daraxonrasib targets RAS mutations, which drive tumor growth in more than 90% of pancreatic cancer cases

** The drug was generally well tolerated, with no new safety concerns - company

** "This effectively unlocks daraxonrasib becoming the next standard of care in PDAC," said J.P. Morgan analyst Brian Cheng

** RVMD plans to seek regulatory approval; drug has FDA breakthrough and orphan designations

** Including session's move, shares up ~21% this year

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))